The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Related to this article
ASH updates myelofibrosis care with expanded molecular testing, earlier transplant consultation, tailored JAK inhibitor use, anemia strategies, and aspirin guidance to reduce clot risk.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FET-PET, Molecular Testing, and Personalized Treatment Push Brain Tumor Care Forward
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
How to Select First-Line Immunotherapy for Metastatic NSCLC
5